Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm AdministrationBenzinga • 07/15/21
Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT NewsBenzinga • 07/15/21
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple SclerosisGlobeNewsWire • 07/12/21
FDA calls for investigation into its own approval of Biogen's Alzheimer's drugMarket Watch • 07/09/21
Biogen stock falls after FDA calls for federal investigation into Alzheimer's drug approvalCNBC • 07/09/21
Should Biogen Worry About a Congressional Investigation Into Its Alzheimer's Disease Drug?The Motley Fool • 07/09/21
Collaboration Between AbbVie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and DiseaseGlobeNewsWire • 07/08/21
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's PatientsBenzinga • 07/08/21
Biogen updates label for Alzheimer's disease drug to say it should be used in people with 'mild' diseaseMarket Watch • 07/08/21
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical TrialsGlobeNewsWire • 07/08/21
